King Pharmaceuticals Inc. (KG) is in the Pharma Industry

• Sort by
• View by Content Type
• View Related Content by Tag

• Alpharma Rejects King Pharma's Offer; What Now?

  The M & A Researcher submits: Alpharma ALO has announced the rejection of King Pharmaceuticals' KG unsolicited $37 per share offer as "financially inadequate." ALO has also disclosed the following with respect to third-party interest: by The M & A Researcher

  External links 2008-09-29

  Tags: Healthcare, Alpharma Inc., King Pharmaceuticals Inc.

• Friday Options Update: LEH, SCHW, AKAM, KG, APO, TGT, ORCL, KO

  Rebecca Engmann Darst contributed to this report. Lehman Brothers LEH – Shares in Lehman Brothers bounded sharply out of the gate with a 10% gain to $15.09 on speculation that the firm might be bought by Korea Development Bank. The move in Lehman comes a day after respected analyst Richard...

  External links 2008-08-22

  Tags: US Market, Akamai Technologies Inc., American Community Properties Trust, King Pharmaceuticals Inc., Coca-Cola Co., Lehman Brothers Holdings Inc., Oracle Corp., Charles Schwab & Co. Inc., Target Corp.

• King Pharmaceuticals, Inc. Q2 2008 Earnings Call Transcript

  Question-and-Answer SessionThank you. The floor is now open for questions. [Operator Instructions]. Our first question comes from Greg Gilbert of Merrill Lynch. Please state your question. Gregory Gilbert - Merrill Lynch Thanks. Good morning. Can you give us your latest thoughts on the competitive environment in the Thrombin market...

  Earnings calls 2008-08-07

  Tags: King Pharmaceuticals Inc.

• Earnings Preview: King Pharmaceuticals

  King Pharmaceuticals KG is expected to report Q2 earnings before market open Thursday Aug. 7, with a conference call scheduled for 11:00 am ET.Guidance Analysts are looking for a profit of 32c on revenue of $397.28M. The consensus is wide, 25c to 37c for EPS, and $361M to $423M for...

  External links 2008-08-06

  Tags: Healthcare, King Pharmaceuticals Inc.

• King Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript

  Question-and-Answer SessionThank you, Mr. Squicciarino. [Operator Instructions]. And our first question comes from Donald Ellis from Thomas Weisel Partners. Please go ahead. Donald Ellis - Thomas Weisel Partners Thank you, and good morning. First question is regarding SKELAXIN. Year-over-year prescriptions were down about 8.5%, but the revenue reported was...

  Earnings calls 2008-05-08

  Tags: King Pharmaceuticals Inc.

• King Pharmaceuticals, Inc. Q4 2007 Earnings Call Transcript

  Question-and-Answer SessionThank you Mr. Squicciarino. The floor is now open for questions. [Operator Instructions]. Our first question comes from Corey Davis. Go ahead Corey. Corey Davis - Natexis Bleichroeder Thanks very much. I had a couple... first how would you describe the pricing dynamics in the thrombin market now...

  Earnings calls 2008-03-04

  Tags: King Pharmaceuticals Inc.

• King Pharmaceuticals Inc. Q3 2007 Earnings Call Transcript

  Question-and-Answer Session Operator Thank you Mr. Markison. [Operator Instructions]. Our first question comes from Adam Greene of J. P. Morgan, please go ahead. Adam Greene - J.P. Morgan Thanks good morning. First, your gross margin guidance of 72% to...

  Earnings calls 2007-11-08

  Tags: King Pharmaceuticals Inc.

Additional Resources

• Alpharma Board of Directors Unanimously Rejects King Pharmaceuticals' Unsolicited Tender Offer as "Financially Inadequate"

  Advises Shareholders Not to Tender Shares as Alpharma Has "Received Expressions of Interest from Multiple Parties" in Pursuing a Transaction Process to Explore Strategic Alternatives Continues with Goal of a Transaction at a Price In Excess of $37.00 Per Share King Continues to Be Invited to...

  Articles 2008-09-26

• King Pharmaceuticals Responds to Alpharma Inc

  BRISTOL, Tenn. -- King Pharmaceuticals, Inc. (NYSE: KG) today issued the following statement in response to an announcement by Alpharma Inc. (NYSE: ALO) regarding King's offer to acquire Alpharma for $37.00 per share in cash. [TABLE OMITTED] On September 12, 2008, King Pharmaceuticals announced that it commenced a...

  Articles 2008-09-26

• King Pharmaceuticals Provides Updated Replay Information for Conference Call Regarding Proposed Acquisition of Alpharma

  BRISTOL, Tenn. -- King Pharmaceuticals, Inc. (NYSE:KG) today held a conference call at 10:00 AM ET to discuss its proposal to acquire Alpharma Inc. (NYSE:ALO) for $33.00 per share in cash. Playback of the conference call and the webcast will be available for replay through the close of...

  Articles 2008-08-22

• King Proposes Acquisition of Alpharma for $33 Per Share in Cash

  Represents Equity Value of $1.4 Billion Offers a Significant Premium to Alpharma Stockholders Combined Entity Would Create a Leading Specialty Pharmaceutical Company with Greater Commercialization Capabilities, Expanded Portfolio of Pain Management Products and a Strengthened Pipeline BRISTOL, Tenn. -- King Pharmaceuticals, Inc. (NYSE: KG)...

  Articles 2008-08-22

• Alpharma Responds to Unsolicited Proposal by King Pharmaceuticals, Inc

  BRIDGEWATER, N.J. -- Alpharma, Inc. (NYSE: ALO), a global specialty pharmaceutical company, confirmed that it received this morning an unsolicited, non-binding proposal from King Pharmaceuticals, Inc. (NYSE: KG) to acquire all of the outstanding shares of Alpharma for $33.00 per share in cash. Alpharma said today's proposal was identical in...

  Articles 2008-08-22

• Pain Therapeutics and King Pharmaceuticals Announce Final Data of REMOXY Phase III Study at World Pain Congress in Scotland

  GLASGOW, Scotland -- Pain Therapeutics, Inc. (NASDAQ: PTIE) and King Pharmaceuticals, Inc. (NYSE: KG) today presented the final data set of a previously announced pivotal Phase III study of REMOXY([R]), an investigational drug to treat chronic pain. The final data confirm REMOXY provides effective around-the-clock analgesia within a patented formulation...

  Articles 2008-08-19

• BellwetherReport.com Analyst Report on NFS, DVN, KG and MF

  BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased analyst opinions on thecompanies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have once again scheduled interviews with a...

  Articles 2008-08-07

• King Pharmaceuticals Supports Time To Talk™ Education Campaign

  Study Highlights New Trend in Motivation behind Teen Abuse, Program Offers Help for Parents BRISTOL, Tenn. -- King Pharmaceuticals, Inc. (NYSE:KG) commends the Partnership for a Drug-Free America([R]) on the second anniversary of the Time To Talk[TM] (www.timetotalk.org) campaign, which encourages parents to talk with their kids about...

  Articles 2008-08-06

• CytoDyn on Target with Target for Electronic FDA Application

  GLORIETA, N.M. & NEW YORK -- CytoDyn, Inc. (Pink Sheets:CYDY) has selected Target Health, Inc. for the preparation and electronic filing of CytoDyn's upcoming FDA application using Target Health's proprietary e*CRF[R] system. The advantage of Target Health is based on its core expertise in regulatory affairs and clinical research, and...

  Articles 2008-07-28

• King Pharmaceuticals Announces Date for Release of Second-Quarter 2008 Financial Results and Conference Call

  BRISTOL, Tenn. -- King Pharmaceuticals, Inc. (NYSE:KG) reported today that the Company plans to announce its financial results for the second quarter ended June 30, 2008, prior to the market open on Thursday, August 7, 2008. The Company also plans to provide a live conference call which may include discussion...

  Articles 2008-07-24

• Sandoz launches ramipril

  Sandoz Inc. has introduced ramipril, a generic equivalent of King Pharmaceuticals Inc.'s Altace, in the United States. Sandoz is marketing ramipril capsules in 1.25-mg, 2.5-mg, 5-mg and 10-mg strengths...

  Articles 2008-07-14

• Research and Markets: Benchmark Serviers Performance Against Key Rivals In The Ethical Pharmaceutical Sector

  DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/5e9514/les_laboratoires_s) has announced the addition of the "Les Laboratoires Servier: PharmaVitae Profile" company profile to their offering. This analysis examines the historical and forecast performance for Servier in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio...

  Articles 2008-07-09

• Comprehensive Evaluation of Pharmaceutical Wholesalers and Distributors in the UK

  DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/249b33/pharmaceutical_who) has announced the addition of the "Pharmaceutical Wholesalers & Distributors UK - Portfolio Analysis" report to their offering. The Plimsoll Portfolio Analysis - Pharmaceutical Wholesalers & Distributors is a comprehensive evaluation of the UK market. The revised and...

  Articles 2008-07-02